The document discusses open innovation and intellectual property transfer across borders. It describes opportunities such as licensing options and joint IP clauses in research collaborations. However, it also notes risks like interference with background IP, exclusivity deals, and limitations of joint ownership. The document advocates treating IP to both give and take in partnerships while protecting a company's core business and future activities.

1. Open innovation – Opportunities and risks of IP transfer across borders Martin Bonenfant, Ph.D. NRC – IRAP Global Innovation Conference February 24 th , 2011

3. An overview © 2011 Medicago Inc. All rights reserved Established 1999 Employees 100+ Headquarters Quebec City, Canada Focus Vaccines Vaccine technology Virus-like particles (VLPs) Manufacturing technology Transient expression in tobacco Product pipeline Pandemic influenza – Phase II Seasonal influenza –Phase I

10. Medicago – Think Global, Act Local Unique technology + Unique market niche (influenza vaccines) Preferred expansion route : Implantation of subsidiaries - Increases chances of local partnerships - Gives access to local fundings - Decreases involvement/risks of parent company - Eases technology and knowledge transfer (all internal) - Lots of staff mobility in both ways - Cultural barriers - Differences in education = Difference in skills? - Status of IP enforcement + - Careful at protecting core business